Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VRAX · NASDAQ · In Vitro & In Vivo Diagnostic Substances · Foreign private issuer
Virax Biolabs Group (VRAX) · oqro.io/stocks/VRAX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Virax Biolabs Group is on record in SEC filings since 2006.
No open-market sale by an insider of Virax Biolabs Group (VRAX) was filed with the SEC in the last 90 days.
No trade in Virax Biolabs Group (VRAX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.3319−0.0491 (−12.89%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−96.7% (−$9.71) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $10.05 on Nov 20, 2025 to $0.3319 on Nov 20, 2026 (−96.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
In Vitro & In Vivo Diagnostic Substances company based in Lanarkshire, United Kingdom. Foreign private issuer: reports on Form 20-F or 40-F.
In Vitro & In Vivo Diagnostic Substances company based in Lanarkshire, United Kingdom. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−96.7%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6,682 shares sold short, −25.6% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 4,000 words.
Virax Biolabs Group Limited is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of its own, it conducts substantially all of its operations through subsidiaries in the United Kingdom, the United States and China and has been operating since 2013. The Company is a biotechnology company focused on immune response detection, T cell immune profiling and the development of in vitro diagnostic technologies for viral and immune-mediated diseases. The Company’s current strategic focus is on post-acute infection syndromes (“PAIS”) and related areas of chronic immune dysfunction. The Company’s principal development activities are centered on T cell-based immune profiling and in vitro diagnostics.
And 5 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Jul 6, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Jul 6, 2026, compared with the one filed Jul 2, 2025. Read the filing
All 48 risk factor headings match the year before, give or take wording.
Source: SEC EDGAR, Form 20-F filed Jul 6, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 59.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.4% on ATS, 53.7% with other brokers), above its 16-week average of 49.2%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (20.9%), LEVEL ATS (15.2%), INTELLIGENT CROSS LLC (10.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
No Schedule 13D or 13G filing on VRAX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Records